Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases—A prospective randomised placebo-controlled multicentre study
| Autor: | Mikael Eriksson, Per Pfeiffer, Jörgen Hansen, Stig Strid, Sam Rotstein, Jonas Söderqvist, Ulla Glas, Ulf Bandmann |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Hypercalcaemia medicine.medical_treatment Bone Neoplasms Breast Neoplasms Placebo Gastroenterology Placebos Breast cancer Double-Blind Method Internal medicine medicine Humans Hypocalcaemia Prospective Studies Infusions Intravenous Adverse effect Prospective cohort study Aged Aged 80 and over Chemotherapy Hypocalcemia business.industry Blood Proteins Middle Aged medicine.disease Surgery Hydroxyproline Oncology Hypercalcemia Fluid Therapy Clodronic acid Calcium Female Clodronic Acid business medicine.drug |
| Zdroj: | European Journal of Cancer. 28:890-893 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(92)90143-p |
| Popis: | In a double blind randomised multicentre study the effect of intravenous clodronate plus hydration was compared with placebo plus hydration in the treatment of hypercalcaemia in breast cancer patients with bone metastases. The patients were treated either with hydration plus clodronate 300 mg/day or hydration plus placebo, up to 7 days or until serum ionised calcium was below 1.4 mmol/l. 25 patients received clodronate and 19 placebo. A significant difference in favour of clodronate was observed in the time to reach normocalcaemia (P = 0.004) and in the number of patients achieving normocalcaemia (P = 0.0003). 17 patients of 21 evaluable patients on clodronate achieved normocalcaemia compared with 4 of 19 patients on placebo. The only adverse event clearly associated with clodronate was symptomatic hypocalcaemia in 1 patient. Thus, clodronate seems to be a safe and highly efficacious drug for the treatment of hypercalcaemia in breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|